Elevated peripheral blood glutamate levels in major depressive disorder

Código QR

Elevated peripheral blood glutamate levels in major depressive disorder

Masatoshi Inoshita,1 Hidehiro Umehara,1 Shin-ya Watanabe,1 Masahito Nakataki,1 Makoto Kinoshita,1 Yukiko Tomioka,1 Atsushi Tajima,2 Shusuke Numata,1 Tetsuro Ohmori1 1Department of Psychiatry, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan; 2Department of Bioinformati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inoshita M, Umehara H, Watanabe S, Nakataki M, Kinoshita M, Tomioka Y, Tajima A, Numata S, Ohmori T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	glutamate major depressive disorder blood association study meta-analysis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/54d0d76e83924955bf880a6f6e951cdc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Pioglitazone could induce remission in major depression: a meta-analysis
por: Colle R, et al.
Publicado: (2016)

Gene expression-based biological test for major depressive disorder: an advanced study
por: Watanabe S, et al.
Publicado: (2017)

Evaluation of cognitive impairment in patients with major depressive disorder in remission
por: Mustafa Ali, et al.
Publicado: (2021)

The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
por: Li G, et al.
Publicado: (2016)

Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
por: Huang Q, et al.
Publicado: (2016)

Left Dorsolateral Prefrontal Cortex Glx/tCr Predicts Efficacy of High Frequency 4- to 6-Week rTMS Treatment and Is Associated With Symptom Improvement in Adults With Major Depressive Disorder: Findings From a Pilot Study
por: Pallab Bhattacharyya, et al.
Publicado: (2021)

No association between BDNFVal66Met polymorphism and treatment response in obsessive-compulsive disorder in the Japanese population
por: Umehara H, et al.
Publicado: (2016)

A single-nucleotide polymorphism influences brain morphology in drug-naïve patients with major depressive disorder
por: Katsuki A, et al.
Publicado: (2019)

Predictors of Major Depressive Disorder in Older People
por: Susana Sousa, et al.
Publicado: (2021)

Potential Genetic Overlap Between Insomnia and Sleep Symptoms in Major Depressive Disorder: A Polygenic Risk Score Analysis
por: Lindsay M. Melhuish Beaupre, et al.
Publicado: (2021)

A thermophilic microorganism from Deception Island, Antarctica with a thermostable glutamate dehydrogenase activity
por: Flores,Patricio A. M., et al.
Publicado: (2018)

Functional impairment in patients with major depressive disorder: the 2-year PERFORM study
por: Hammer-Helmich L, et al.
Publicado: (2018)

Associations among depression severity, painful physical symptoms, and social and occupational functioning impairment in patients with major depressive disorder: a 3-month, prospective, observational study
por: Harada E, et al.
Publicado: (2017)

Identifying factors associated with the hospital readmission rate among patients with major depressive disorder
por: Sharareh Parami, et al.
Publicado: (2021)

Childhood Emotional Neglect Is Associated With Low Social Support in Chinese Patients With Major Depressive Disorder
por: Xuemei Qin, et al.
Publicado: (2021)

Prevalence of major depressive disorder among hemodialysis patients compared with healthy people in Japan using the Structured Clinical Interview for DSM-IV
por: Tomita T, et al.
Publicado: (2016)

Preliminary Study on Changes of Sleep EEG Power and Plasma Melatonin in Male Patients With Major Depressive Disorder After 8 Weeks Treatment
por: Xue-Qin Wang, et al.
Publicado: (2021)

Chronic Stress in a Rat Model of Depression Disturbs the Glutamine–Glutamate–GABA Cycle in the Striatum, Hippocampus, and Cerebellum
por: Xu S, et al.
Publicado: (2020)

5-HTR1A and 5-HTR2A genetic polymorphisms and SSRI antidepressant response in depressive Chinese patients
por: Dong ZQ, et al.
Publicado: (2016)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017)

Lifetime Major Discrimination Experiences Moderate the Impact of Depressive Symptoms on Chronic Conditions among Black Americans
por: Kia Skrine Jeffers, et al.
Publicado: (2021)

Association between anxious distress in a major depressive episode and bipolarity
por: Sugawara H, et al.
Publicado: (2019)

Amygdalar κ-opioid receptor-dependent upregulating glutamate transporter 1 mediates depressive-like behaviors of opioid abstinence
por: Gui-Ying Zan, et al.
Publicado: (2021)

Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
por: Saragoussi D, et al.
Publicado: (2018)

Face Recognition Brain Functional Connectivity in Patients With Major Depression: A Brain Source Localization Study by ERP
por: Lei Lei, et al.
Publicado: (2021)

Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
por: Otsubo T, et al.
Publicado: (2018)

Development and Validation of 3-Month Major Post-Stroke Depression Prediction Nomogram After Acute Ischemic Stroke Onset
por: Li G, et al.
Publicado: (2021)

Sex differences in gut microbiota in patients with major depressive disorder
por: Chen JJ, et al.
Publicado: (2018)

Levels of serum immunomodulators and alterations with electroconvulsive therapy in treatment-resistant major depression
por: Zincir S, et al.
Publicado: (2016)

Shared Genetic Liability and Causal Associations Between Major Depressive Disorder and Cardiovascular Diseases
por: Fuquan Zhang, et al.
Publicado: (2021)

Tratamientos farmacológicos antidepresivos
por: Heerlein,Andrés
Publicado: (2002)

Temperament, personality, and treatment outcome in major depression: a 6-month preliminary prospective study
por: Kudo Y, et al.
Publicado: (2016)

Types I and III Parotid Collagen Variations and Serum Biochemical Parameters in Obese Rats Exposed to Monosodium Glutamate
por: Roa,Ignacio, et al.
Publicado: (2020)

AUTOANTIBODIES TO GLUTAMIC ACID DECARBOXYLASE AS A PATHOGENETIC MARKER OF TYPE I DIABETES MELLITUS
por: N. V. Piven, et al.
Publicado: (2014)

Plasma complement component 4 increases in patients with major depressive disorder
por: Wei J, et al.
Publicado: (2017)

Residual symptoms in patients with partial versus complete remission of a major depressive disorder episode: patterns of painful physical symptoms in depression
por: Harada E, et al.
Publicado: (2016)

The level of IL-6 was associated with sleep disturbances in patients with major depressive disorder
por: Wang M, et al.
Publicado: (2019)

Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder
por: Tsutsumi T, et al.
Publicado: (2016)

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
por: Yoshimura R, et al.
Publicado: (2017)

Metabotropic glutamate receptor 5 may be involved in macrophage plasticity
por: Shanshiashvili,Lali, et al.
Publicado: (2017)